Published in Chest on May 27, 2010
REVEAL Registry™: Registry to Evaluate Early And Long-term PAH Disease Management | NCT00370214
Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest (2012) 2.59
Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension. Am J Respir Crit Care Med (2015) 1.58
Right ventricular dysfunction in systemic sclerosis-associated pulmonary arterial hypertension. Circ Heart Fail (2013) 1.21
Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. Ann Rheum Dis (2012) 1.00
Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. Chest (2014) 0.96
Pulmonary arterial hypertension in systemic lupus erythematosus: current status and future direction. Clin Dev Immunol (2012) 0.95
Exercise training in pulmonary arterial hypertension associated with connective tissue diseases. Arthritis Res Ther (2012) 0.93
Pulmonary hypertension in systemic lupus erythematosus: a systematic review and analysis of 642 cases in Chinese population. Rheumatol Int (2012) 0.93
N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study. Arthritis Res Ther (2012) 0.90
Clinical features and independent predictors of pulmonary arterial hypertension in systemic lupus erythematosus. Rheumatol Int (2011) 0.89
Three-dimensional analysis of right ventricular shape and function in pulmonary hypertension. Pulm Circ (2012) 0.88
Baseline Characteristics of the Korean Registry of Pulmonary Arterial Hypertension. J Korean Med Sci (2015) 0.85
Latest advances in connective tissue disorders. Ther Adv Musculoskelet Dis (2013) 0.85
Prevalence of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review of the literature. Clin Rheumatol (2013) 0.85
Comparison of Treatment Response in Idiopathic and Connective Tissue Disease-associated Pulmonary Arterial Hypertension. Am J Respir Crit Care Med (2015) 0.85
Pulmonary hypertension: diagnostic and therapeutic challenges. Ther Clin Risk Manag (2015) 0.84
Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study. Arthritis Res Ther (2012) 0.84
Characteristics of interstitial fibrosis and inflammatory cell infiltration in right ventricles of systemic sclerosis-associated pulmonary arterial hypertension. Int J Rheumatol (2010) 0.83
Where do we go from here? Reappraising the data on anticoagulation in pulmonary arterial hypertension. J Thorac Dis (2016) 0.82
Diagnosis and risk stratification in patients with anti-RNP autoimmunity. Lupus (2015) 0.82
Health-related Quality of Life and Survival in Pulmonary Arterial Hypertension. Ann Am Thorac Soc (2016) 0.81
Survival in systemic sclerosis-pulmonary arterial hypertension by serum autoantibody status in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Registry. Semin Arthritis Rheum (2015) 0.81
Metabolic and hormonal derangements in pulmonary hypertension: from mouse to man. Int J Clin Pract Suppl (2010) 0.81
Pulmonary arterial hypertension associated with connective tissue disease: meta-analysis of clinical trials. BMJ Open (2013) 0.80
Significance of pulmonary arterial pressure as a prognostic indicator in lung-dominant connective tissue disease. PLoS One (2014) 0.80
Baseline Characteristics and Risk Factors of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus Patients. Medicine (Baltimore) (2016) 0.79
Pulmonary hypertension in women. Expert Rev Cardiovasc Ther (2010) 0.79
Serum endothelin-1 and NT-proBNP, but not ADMA, endoglin and TIMP-1 levels, reflect impaired right ventricular function in patients with systemic sclerosis. Clin Rheumatol (2013) 0.79
Survival outcomes in severe congenital versus non-congenital pulmonary hypertension. Heart Asia (2016) 0.79
Survival in pulmonary hypertension registries: the importance of incident cases. Chest (2011) 0.78
Severity of systemic sclerosis-associated pulmonary arterial hypertension in African Americans. Medicine (Baltimore) (2014) 0.78
Pulmonary hypertension in parenchymal lung disease. Pulm Med (2012) 0.77
Exaggerated increase of exercise-induced pulmonary artery pressure in systemic sclerosis patients predominantly results from left ventricular diastolic dysfunction. Clin Res Cardiol (2013) 0.77
Economic evaluation of exercise training in patients with pulmonary hypertension. Lung (2014) 0.77
Screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension: a systematic review. Semin Arthritis Rheum (2013) 0.77
Lung transplantation for pulmonary hypertension. Pulm Circ (2011) 0.77
Sex differences in the pulmonary circulation: implications for pulmonary hypertension. Am J Physiol Heart Circ Physiol (2014) 0.77
Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. Ann Rheum Dis (2016) 0.76
Challenges and opportunities in treating inflammation associated with pulmonary hypertension. Expert Rev Cardiovasc Ther (2016) 0.76
Right ventricular remodeling in idiopathic and scleroderma-associated pulmonary arterial hypertension: two distinct phenotypes. Pulm Circ (2015) 0.76
Prevalence of Pulmonary Arterial Hypertension in Korean Adult Patients with Systemic Sclerosis: Result of a Pilot Echocardiographic Screening Study. J Cardiovasc Ultrasound (2016) 0.75
Multicentre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocol. BMJ Open (2016) 0.75
Systemic lupus erythematosus and pulmonary arterial hypertension: links, risks, and management strategies. Open Access Rheumatol (2016) 0.75
Association Between Initial Oral Therapy and Outcomes in Systemic Sclerosis-Related Pulmonary Arterial Hypertension. Arthritis Rheumatol (2016) 0.75
Connective tissue disease-associated pulmonary arterial hypertension. F1000Prime Rep (2015) 0.75
Pulmonary venous occlusion and death in pulmonary arterial hypertension: survival analyses using radiographic surrogates. BMC Pulm Med (2011) 0.75
Adverse Events in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension. Arthritis Rheumatol (2015) 0.75
Epidemiology and disease characteristics of systemic sclerosis-related pulmonary arterial hypertension: results from a real-life screening programme. Arthritis Res Ther (2017) 0.75
Follow-up tricuspid annular plane systolic excursion predicts survival in pulmonary arterial hypertension. Pulm Circ (2017) 0.75
Kidney dysfunction in patients with pulmonary arterial hypertension. Pulm Circ (2017) 0.75
Cardiopulmonary Manifestations of Collagen Vascular Diseases. Curr Rheumatol Rep (2017) 0.75
Autoimmune disease mouse model exhibits pulmonary arterial hypertension. PLoS One (2017) 0.75
Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol (2009) 12.05
Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med (2006) 6.06
Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis (2007) 4.88
Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest (2009) 4.08
Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med (2009) 3.96
Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med (2008) 3.67
Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med (2000) 3.57
Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis (2003) 2.85
Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation (2000) 2.78
Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol (2002) 2.50
Is pulmonary arterial hypertension really a late complication of systemic sclerosis? Chest (2009) 2.40
Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis (2006) 2.28
Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J (2006) 2.16
Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum (2006) 2.04
Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum (2003) 1.94
Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest (2003) 1.90
High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum (2008) 1.90
Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension. Eur Respir J (2009) 1.85
Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart (2005) 1.73
Pattern and distribution of myocardial fibrosis in systemic sclerosis: a delayed enhanced magnetic resonance imaging study. Arthritis Rheum (2007) 1.62
Raynaud's phenomenon. Lancet (2001) 1.58
Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol (1996) 1.50
Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol (2007) 1.42
Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum (2008) 1.40
Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum (2009) 1.40
Pulmonary veno-occlusive disease. Eur Respir J (2009) 1.37
Design of the REVEAL registry for US patients with pulmonary arterial hypertension. Mayo Clin Proc (2008) 1.36
Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest (2006) 1.29
Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum (2006) 1.21
The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis Rheum (2009) 1.18
Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases. J Heart Lung Transplant (2005) 1.09
Increased mortality in African Americans with idiopathic pulmonary arterial hypertension. J Natl Med Assoc (2008) 1.07
Pulmonary arterial hypertension associated to connective tissue diseases. Lupus (2005) 1.03
Anticardiolipin and anti-beta2 glycoprotein I antibodies and lupus-like anticoagulant: prevalence and significance in systemic sclerosis. Br J Dermatol (2007) 1.01
Carbon monoxide diffusing capacity as predictor of outcome in systemic sclerosis. Am J Med (1984) 0.97
The presence of anti-centromere antibodies may predict progression of estimated pulmonary arterial systolic pressure in systemic sclerosis. Scand J Rheumatol (2008) 0.91
Pulmonary capillary endothelial metabolic dysfunction: severity in pulmonary arterial hypertension related to connective tissue disease versus idiopathic pulmonary arterial hypertension. Arthritis Rheum (2008) 0.91
Clinical aspects of pulmonary hypertension in patients with systemic lupus erythematosus and in patients with idiopathic pulmonary arterial hypertension. Clin Rheumatol (2006) 0.90
Pulmonary veno-occlusive disease and scleroderma associated pulmonary hypertension. J Rheumatol (2006) 0.84
Bosentan therapy for pulmonary arterial hypertension. N Engl J Med (2002) 11.18
Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol (2009) 5.31
Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation (2010) 4.66
Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest (2009) 4.08
Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med (2009) 3.96
Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol (2004) 3.63
Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med (2006) 3.59
Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury. Am J Respir Crit Care Med (2004) 3.59
Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med (2008) 3.13
The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Chest (2010) 3.02
Transplantation for idiopathic pulmonary arterial hypertension: improvement in the lung allocation score era. Circulation (2013) 2.87
An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest (2012) 2.82
Endothelial dysfunction in pulmonary hypertension. Circulation (2004) 2.82
Sphingosine 1-phosphate reduces vascular leak in murine and canine models of acute lung injury. Am J Respir Crit Care Med (2004) 2.73
Temporal response of the human virome to immunosuppression and antiviral therapy. Cell (2013) 2.72
Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy. Circulation (2006) 2.72
Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation (2013) 2.64
Clinical risk factors for portopulmonary hypertension. Hepatology (2008) 2.62
Tricuspid annular plane systolic excursion is a robust outcome measure in systemic sclerosis-associated pulmonary arterial hypertension. J Rheumatol (2011) 2.48
An animal model of autoimmune emphysema. Am J Respir Crit Care Med (2004) 2.40
Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol (2003) 2.23
An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med (2014) 2.23
Comprehensive invasive and noninvasive approach to the right ventricle-pulmonary circulation unit: state of the art and clinical and research implications. Circulation (2009) 2.17
Sex differences in mortality after acute myocardial infarction: changes from 1994 to 2006. Arch Intern Med (2009) 2.09
Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum (2006) 2.04
Perspectives on oral pulmonary hypertension therapies recently approved by the U.S. Food and Drug Administration. Ann Am Thorac Soc (2015) 2.02
Benefit of transferring ST-segment-elevation myocardial infarction patients for percutaneous coronary intervention compared with administration of onsite fibrinolytic declines as delays increase. Circulation (2011) 1.95
Pulmonary capillary wedge pressure augments right ventricular pulsatile loading. Circulation (2011) 1.92
Evaluation and management of the patient with pulmonary arterial hypertension. Ann Intern Med (2005) 1.91
Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT. Circulation (2011) 1.91
Use of consomic rats for genomic insights into ventilator-associated lung injury. Am J Physiol Lung Cell Mol Physiol (2007) 1.86
Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med (2006) 1.86
Trends in quality of care for patients with acute myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. Am Heart J (2008) 1.81
Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL Registry. J Heart Lung Transplant (2013) 1.79
Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol (2009) 1.78
Lung transplant airway hypoxia: a diathesis to fibrosis? Am J Respir Crit Care Med (2010) 1.77
PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support. Circ Heart Fail (2008) 1.75
The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe. Haematologica (2012) 1.72
Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest (2003) 1.71
Increased regulatory and decreased CD8+ cytotoxic T cells in the blood of patients with idiopathic pulmonary arterial hypertension. Respiration (2007) 1.67
Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Circulation (2011) 1.67
Inhibiting lung elastase activity enables lung growth in mechanically ventilated newborn mice. Am J Respir Crit Care Med (2011) 1.67
Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood (2011) 1.64
End points and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol (2009) 1.63
The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest (2011) 1.58
Epidermal growth factor receptor (EGFR) regulates mechanical ventilation-induced lung injury in mice. Transl Res (2008) 1.57
Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience. Chest (2008) 1.57
Modulation of inducible nitric oxide synthase by hypoxia in pulmonary artery endothelial cells. Am J Respir Cell Mol Biol (2002) 1.55
Disruption of Nrf2 impairs the resolution of hyperoxia-induced acute lung injury and inflammation in mice. J Immunol (2009) 1.53
Asthma control, severity, and quality of life: quantifying the effect of uncontrolled disease. J Allergy Clin Immunol (2007) 1.50
Recent asthma exacerbations: a key predictor of future exacerbations. Respir Med (2006) 1.49
Aircraft cabin air recirculation and symptoms of the common cold. JAMA (2002) 1.48
Increased resource use in lung transplant admissions in the lung allocation score era. Am J Respir Crit Care Med (2015) 1.45
Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med (2009) 1.44
Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med (2010) 1.44
Is there a benefit to early angiography in patients with ST-segment depression myocardial infarction? An observational study. Am Heart J (2002) 1.44
Association of bleeding and in-hospital mortality in black and white patients with st-segment-elevation myocardial infarction receiving reperfusion. Circulation (2012) 1.44
Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling. Am J Respir Crit Care Med (2007) 1.42
Severity assessment in asthma: An evolving concept. J Allergy Clin Immunol (2005) 1.42
Mechanical stress activates xanthine oxidoreductase through MAP kinase-dependent pathways. Am J Physiol Lung Cell Mol Physiol (2006) 1.42
Genetic and pharmacologic evidence links oxidative stress to ventilator-induced lung injury in mice. Am J Respir Crit Care Med (2007) 1.41
Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum (2009) 1.40
Cytoskeletal changes in hypoxic pulmonary endothelial cells are dependent on MAPK-activated protein kinase MK2. J Biol Chem (2002) 1.40
Pathobiology of pulmonary arterial hypertension and right ventricular failure. Eur Respir J (2012) 1.39
Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe asthma exacerbations in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. J Allergy Clin Immunol (2009) 1.38
Microvascular destruction identifies murine allografts that cannot be rescued from airway fibrosis. J Clin Invest (2007) 1.38
Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension. Am J Respir Crit Care Med (2008) 1.38
Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol (2003) 1.37
Design of the REVEAL registry for US patients with pulmonary arterial hypertension. Mayo Clin Proc (2008) 1.36
Adenovirus-mediated HIF-1α gene transfer promotes repair of mouse airway allograft microvasculature and attenuates chronic rejection. J Clin Invest (2011) 1.35
Endogenous signals released from necrotic cells augment inflammatory responses to bacterial endotoxin. Immunol Lett (2007) 1.35
Inducible nitric oxide synthase contributes to ventilator-induced lung injury. Am J Respir Crit Care Med (2005) 1.35
Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Heart Circ Physiol (2003) 1.34
Regulation of endothelial barrier function by reactive oxygen and nitrogen species. Microvasc Res (2008) 1.34
Schistosomiasis-induced experimental pulmonary hypertension: role of interleukin-13 signaling. Am J Pathol (2010) 1.33
Regulatory T cells limit vascular endothelial injury and prevent pulmonary hypertension. Circ Res (2011) 1.31
Disruption of the apelin-APJ system worsens hypoxia-induced pulmonary hypertension. Arterioscler Thromb Vasc Biol (2011) 1.30
Regression of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Lung Cell Mol Physiol (2007) 1.30
Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. Chest (2011) 1.29
Identification of candidate genes in scleroderma-related pulmonary arterial hypertension. Transl Res (2008) 1.27
Activation of the STAT pathway in acute lung injury. Am J Physiol Lung Cell Mol Physiol (2004) 1.25
Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI-2). J Am Coll Cardiol (2002) 1.24
Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol (2009) 1.24
Mitogen activated protein kinase activated protein kinase 2 regulates actin polymerization and vascular leak in ventilator associated lung injury. PLoS One (2009) 1.24
Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol (2005) 1.23
Progressive Dyspnea After CABG: Complication of Retained Epicardial Pacing Wires. Ann Thorac Surg (2008) 1.21
Pulmonary hypertension associated with connective tissue disease. Prog Cardiovasc Dis (2003) 1.21
Right ventricular dysfunction in systemic sclerosis-associated pulmonary arterial hypertension. Circ Heart Fail (2013) 1.21
Simultaneous LFA-1 and CD40 ligand antagonism prevents airway remodeling in orthotopic airway transplantation: implications for the role of respiratory epithelium as a modulator of fibrosis. J Immunol (2005) 1.18
CT angiography of pulmonary artery aneurysms in Hughes-Stovin syndrome. AJR Am J Roentgenol (2005) 1.18
Anti-inflammatory effect of thymoquinone in a mouse model of allergic lung inflammation. Int Immunopharmacol (2006) 1.18